Abstracts Archive - Page 374 of 1683 - ATC Abstracts

2020 American Transplant Congress
Remote Steroid Wean is Safe When Compared to Early Wean in Heart Transplant Recipients
B. C. Salgado, J. Krisl, E. A. Graviss, D. T. Nguyen, A. Bhimaraj, A. Guha
Cardiovascular Disease, Heart Failure and Transplant, Houston Methodist Hospital, Houston, TX
*Purpose: The risks and benefits of remote steroid wean in heart transplant recipients is unknown. We compared outcomes in patients undergoing early and remote steroid…
2020 American Transplant Congress
The Effect of UNOS Donor Policy Change on Distance from Recipient Hospital and the Effects on Mortality in Heart Transplantation
P. Kingsford¹, J. P. Li¹, C. J. Lum², A. D. Salimbangon³, G. S. Liu⁴, R. R. Chand⁵, P. Banankhah¹, P. A. Genyk¹, D. Vucicevic¹, K. Pandya¹, J. Rahman¹, M. Fong¹, L. Grazette¹, A. Kiankhooy¹, J. Nattiv¹, S. Hashmi¹, S. B. Nuno¹, J. Pizula¹, D. J. Miklin¹, A. E. Lee¹, K. Yang¹, S. Shah¹, A. S. Vaidya¹, A. M. Wolfson⁶, E. C. DePasquale¹
¹LAC-USC, Los Angeles, CA, ²The Queens Medical Center, Honolulu, HI, ³UCLA Medical Center, Los Angeles, CA, ⁴USC, Los Angeles, CA, ⁵Harbor-UCLA Medical Center, Los Angeles, CA, ⁶University of Arizona Sarver Heart Center, Tucson, AZ
*Purpose: In light of the recent change in the UNOS allocation policy, we sought to evaluate the impact of distance from recipient hospital on mortality.*Methods:…
2020 American Transplant Congress
Risk Epitope Mismatch Does Not Predict Short Term Heart Transplant Outcomes
Y. Moayedi¹, J. McCaughan², E. Henricksen³, B. Mueller⁴, S. Fan⁴, H. J. Ross¹, K. Khush⁵, B. M. Zhang⁶, J. Teuteberg⁵
¹Cardiology, Ted Rogers Centre for Heart Research, University Health Network, University of Toronto, Toronto, ON, Canada, ²HLA Lab, Belfast Trust, Belfast, Ireland, ³Pharmacy, Stanford Healthcare, Stanford, CA, ⁴Computational Program TRCHR, Ted Rogers Centre for Heart Research, University Health Network, University of Toronto, Toronto, ON, Canada, ⁵Cardiology, Stanford University, Stanford, CA, ⁶HLA Lab, Stanford University, Stanford, CA
*Purpose: Heart transplantation (HT) remains the gold standard treatment for end-stage heart failure. Despite significant improvements in short-term outcomes, the median survival after heart transplantation…
2020 American Transplant Congress
Heart Transplantation Outcomes in Patients with Marfan Syndrome: A UNOS Registry Analysis
P. Genyk¹, K. Yang¹, J. Pizula¹, A. Lee¹, D. Miklin¹, S. Shah¹, S. Nuno¹, S. Hashmi¹, J. Nattiv¹, A. Kiankhooy¹, L. Grazette¹, M. Fong¹, J. Rahman¹, K. Pandya¹, A. Vaidya¹, D. Vucicevic², J. Li¹, P. Kingsford¹, P. Banankhah¹, A. Wolfson³, G. Liu¹, R. Chand⁴, E. Depasquale¹
¹Keck Medicine of USC, Los Angeles, CA, ²Newark Beth-Israel Medical Center, Newark, NJ, ³University of Arizona Sarver Heart Center, Tucson, AZ, ⁴Harbor-UCLA Medical Center, Torrance, CA
*Purpose: Marfan syndrome (MS) is an autosomal dominant connective tissue disorder due to a defect in the fibrillin-1 gene. MS patients can develop a discrete…
2020 American Transplant Congress
Foxp3⁺ Innate and TGF-ß⁺ Adaptive Regulatory Immune Cells in Quilty Lesions are Associated with Acceptance of Heart Allograft
S. A. Moore, C. K. Metter, Q. Cai, J. R. Torrealba
University of Texas Southwestern Medical Center, Dallas, TX
*Purpose: To evaluate the cellular composition of Quilty lesions in heart transplant biopsies and their association with acceptance or rejection of cardiac allografts.*Methods: This study…
2020 American Transplant Congress
Sleep Quality and Psychosocial Factors in Liver Transplant Recipients from an Outpatient Follow-Up Clinic in China
X. Zhu, J. Liu, L. Liu, P. Mao
Transplantation Center, Third Xiangya Hospital, Changsha, China
*Purpose: Sleep disturbance is a severe problem in liver transplant recipients; few studies have confirmed the psychosocial factors associated with sleep quality in patients after…
2020 American Transplant Congress
Implementation of a Pharmacist in an Adult Transplant Outpatient Clinic (Kidney, Liver, Pancreas): A Pilot Study – Implant
P. Leveille-Dugas¹, C. Bernard¹, L. Loiselle¹, Y. Zhang¹, C. Coursol¹, K. Mousseau¹, N. Sheehan¹, M. Cantarovich²
¹Pharmacy, McGill University Health Centre, Montréal, QC, Canada, ²Division of Nephrology, Department of Medicine, McGill University Health Centre, Montréal, QC, Canada
*Purpose: Solid organ transplant (SOT) patients require a complex medication regimen which increases the risk of many drug-related problems. The purpose of this study was…
2020 American Transplant Congress
The Reperfusion Response in Plasma of Combined Heart/ Lung Transplanted Patients is Guided by Heart-Associated Cytokine Patterns on Contrast to the Ischemic Injury in Perfusion Solutions Following a Lung-Associated Pattern
C. Falk¹, J. Kühne², L. Radomsky², F. Wandrer², B. Wiegmann³, N. Ledwoch², J. Keil², K. Beushausen², F. Ius³, W. Sommer³, S. Rojas-Hernandez³, I. Tudorache³, A. Haverich³, G. Warnecke³
¹MHH, Institute of Transplant Immunology, Hannover, Germany, ²Institute of Transplant Immunology, Hannover Medical School MHH, Hannover, Germany, ³Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School MHH, Hannover, Germany
*Purpose: Organ-specific differences are discussed for ischemia/reperfusion injury (IRI) in cardiothoracic transplantation but rarely compared directly in a clinical setting. Therefore, we compared a cohort…
2020 American Transplant Congress
Post Heart Transplant Outcomes for Patients with Cardiac Sarcoidosis
G. S. Liu¹, E. C. DePasquale¹, A. M. Wolfson², R. R. Chand³, P. Banankhah¹, J. Nattiv¹, A. D. Salimbangon⁴, P. A. Genyk¹, P. A. Kingsford¹, J. P. Li¹, D. Vucicevic⁵, K. Pandya¹, J. Rahman¹, M. Fong¹, A. S. Vaidya¹
¹Keck Medicine of USC, Los Angeles, CA, ²University of Arizona Sarver Heart Center, Tucson, AZ, ³Harbor-UCLA Medical Center, Los Angeles, CA, ⁴UCLA Medical Center, Los Angeles, CA, ⁵Newark Beth Israel Medical Center, Newark, NJ
*Purpose: Cardiac sarcoidosis (CS) is a known etiology of end-stage dilated, hypertrophic, or arrhythmogenic cardiomyopathies requiring heart transplantation (HT). We sought to evaluate the long-term…
2020 American Transplant Congress
Combined Heart-Liver Transplantation Has Excellent Long-Term Outcomes
J. A. Steadman¹, J. M. Stulak¹, A. L. Clavell², S. S. Kushwaha², B. S. Edwards², N. L. Pereira², B. A. Boilson², A. Behfar², R. J. Rodeheffer², J. A. Dearani¹, T. Taner³, R. C. Daly¹
¹Division of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, ²Division of Cardiovascular Disease, Mayo Clinic, Rochester, MN, ³Division of Transplantation Surgery, Mayo Clinic, Rochester, MN
*Purpose: Combined heart-liver transplants (CHLTx) have been shown to have good short-term outcomes in those with end-stage heart and liver disease: we conducted a comprehensive…